Two 2022 publications address FoundationOne Tracker's value: the November 25 issue of the journal Molecular Oncology, and the September 29 issue of the International Journal of Molecular Sciences.

Foundation Medicine specializes in molecular profiling for cancer; Natera, in cell-free DNA testing.

The current imaging-based care standard for cancer monitoring can be imprecise or inapplicable to all cancer types, negatively impacting patient outcomes. Although immunotherapy is broadly used, assessing therapy response and disease progression remains challenging.

FoundationOne Tracker may complement imaging to better assess treatment response and inform next steps, particularly when imaging is ambiguous. It combines genomic information derived from FoundationOne CDx -- Foundation Medicine's tissue-based comprehensive genomic profiling test -- with Natera's personalized assay design and ctDNA analysis.

The researchers' goal is to allow physicians to serially monitor cancer patients' response to treatments, such as immunotherapy, using a simple blood draw, then use those insights to optimize future treatment decisions.

In February 2022, FoundationOne Tracker was granted U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for use in molecular residual disease detection in early-stage cancer after curative therapy. Although now available through the early access program to a limited number of clinical customers, the companies plan to enable broader U.S. availability later in 2023.

"We developed FoundationOne Tracker to help physicians identify patients who are resistant to their current treatment and may need additional therapy, or those who are responding well to therapy and may benefit from skipping unnecessary doses," said Foundation Medicine CEO Dr. Brian Alexander in a statement. "With this new tool that leverages the molecular fingerprint of the cancer, we hope to maximize the impact of genomic profiling to support a higher degree of personalized cancer care for patients."

Blood test helps diagnose inaccessible brain tumors
A prospective, blinded study by London’s Imperial College researchers showed the TriNetra-Glio liquid biopsy test, which requires 15 mL of blood, can...

Prenetics acquiring majority stake in ACT Genomics, expanding position in cancer genetics, precision oncology
Hong Kong-based Prenetics Global, a genomics and diagnostic testing firm, on Friday announced that it is acquiring a majority stake in Taiwan-based precision...

Illumina supports Norway's pioneering precision medicine study
Illumina announced that it is supporting a precision medicine study in Norway to assess the efficacy of blood-based comprehensive genomic profiling in...

Roche releases genomic profiling kit for cancer research
Roche has released a new genomic profiling kit for cancer research called the Avenio Tumor Tissue Comprehensive Genomic Profiling kit.

Altru Health adopts clinical trial AI from Deep Lens
Deep Lens and Altru Health System have announced a strategic collaboration that will deploy the Viper artificial intelligence (AI)-based clinical trial...

OncoDNA, MyNEO partner on personalized cancer vaccines
OncoDNA and MyNEO will collaborate on the production of personalized cancer vaccines for patients who have run out of treatment options.

Cancer research groups partner for liquid biopsy trial
The Cancer Research Institute and the Mark Foundation for Cancer Research have partnered on a clinical trial to evaluate whether a novel liquid biopsy...